Abiopharma

🔍 Turtle Cameron (Director)

Company: Spyre Therapeutics, Inc. (SYRE)

Report Date: 2026-05-01

Detailed Transactions and Holdings:

• Sold 5,300 shares of Common Stock at $69.54 per share (Direct)
  Date: 2026-05-01 | Code: S | equity_swap_involved: 0 | shares_owned_after: 622,240.00 | transaction_form_type: 4 | Footnotes: F1, F2, F3
• Sold 3,600 shares of Common Stock at $70.77 per share (Direct)
  Date: 2026-05-01 | Code: S | equity_swap_involved: 0 | shares_owned_after: 618,640.00 | transaction_form_type: 4 | Footnotes: F1, F4, F3
• Sold 1,000 shares of Common Stock at $71.76 per share (Direct)
  Date: 2026-05-01 | Code: S | equity_swap_involved: 0 | shares_owned_after: 617,640.00 | transaction_form_type: 4 | Footnotes: F1, F5, F3
• Sold 3,100 shares of Common Stock at $73.14 per share (Direct)
  Date: 2026-05-01 | Code: S | equity_swap_involved: 0 | shares_owned_after: 614,540.00 | transaction_form_type: 4 | Footnotes: F1, F6, F3
• Sold 1,700 shares of Common Stock at $74.23 per share (Direct)
  Date: 2026-05-01 | Code: S | equity_swap_involved: 0 | shares_owned_after: 612,840.00 | transaction_form_type: 4 | Footnotes: F1, F7, F3
• Sold 300 shares of Common Stock at $74.96 per share (Direct)
  Date: 2026-05-01 | Code: S | equity_swap_involved: 0 | shares_owned_after: 612,540.00 | transaction_form_type: 4 | Footnotes: F1, F8, F3

Footnotes:

• F1: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025.
• F2: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $69.25 to $70.24, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range.
• F3: Includes 101,653 shares of common stock that vest in monthly installments through November 2026, subject to the continuing service of the Reporting Person on each vesting date.
• F4: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $70.30 to $71.28, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
• F5: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $71.41 to $72.27, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
• F6: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $72.75 to $73.74, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
• F7: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $73.95 to $74.94, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
• F8: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $74.95 to $74.96, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.